The UTI issue

Every year, 100 million people are diagnosed as having urinary tract infection (UTI). The condition is a worldwide problem.

The widespread prevalence of UTI can be seen in a recent statistic published by NHS England, which shows that 22.7% of the UK’S antibiotic prescriptions are for the condition.

The current UTI testing procedure involves sending samples to a pathology laboratory, which takes some 48 – 72 hours to get back with results. A broad spectrum approach to antibiotic prescription then follows – an approach that very often specifies the wrong antibiotics. This mis-prescribing both slows down treatment and exacerbates an already huge problem, the global challenge of growing antimicrobial resistance (AMR).

The UTI issue

Every year, 100 million people are diagnosed as having urinary tract infection (UTI). The condition is a worldwide problem.

The widespread prevalence of UTI can be seen in a recent statistic published by NHS England, which shows that 22.7% of the UK’S antibiotic prescriptions are for the condition.

The current UTI testing procedure involves sending samples to a pathology laboratory, which takes some 48 – 72 hours to get back with results. A broad spectrum approach to antibiotic prescription then follows – an approach that very often specifies the wrong antibiotics. This mis-prescribing both slows down treatment and exacerbates an already huge problem, the global challenge of growing antimicrobial resistance (AMR).

The PhenUTest solution

PhenUTest’s state-of-the-art technology, currently in development for use in doctors’ surgeries, pharmacies and care homes, can rapidly identify the presence of uropathogens in urine samples and their antibiotic susceptibility (AS).

PhenUTest proprietry technology and intellectual property

PenUTest’s ability to produce test results rapidly is based on our novel observations that changes in bacterial growth in the presence of antibiotics can take place as early as 30 minutes after incubation has started.

This result underpins PhenUTest’s intellectual property around bacterial growth. Other IP covers the cartridge, test instrument and AI algorithms used to identify uropathogens and their antibiotic susceptibility.

Our rapid point-of-care diagnostic technology also has potential in other infections and body fluids.

The company is working towards regulatory approval in the UK, US and Europe.

The PhenUTest solution

PhenUTest’s state-of-the-art technology, currently in development for use in doctors’ surgeries, pharmacies and care homes, can rapidly identify the presence of uropathogens in urine samples and their antibiotic susceptibility (AS).

PhenUTest proprietry technology and intellectual property

PenUTest’s ability to produce test results rapidly is based on our novel observations that changes in bacterial growth in the presence of antibiotics can take place as early as 30 minutes after incubation has started.

This result underpins PhenUTest’s intellectual property around bacterial growth. Other IP covers the cartridge, test instrument and AI algorithms used to identify uropathogens and their antibiotic susceptibility.

Our rapid point-of-care diagnostic technology also has potential in other infections and body fluids.

The company is working towards regulatory approval in the UK, US and Europe.

Radical step forward

PhenUTest represents a radical step forward in UTI diagnosis and treatment, ensuring that patients get appropriate treatment immediately whilst addressing the wider problem of antimicrobial resistance.

Our technology will not only save health services like the NHS £millions but will also reduce the growth of antibiotic resistance.

This test has not been approved or cleared by the U.S. Food and Drug Administration.
The performance characteristics of this test have not been established.

Biosciences Building, Crown Street
Liverpool, L69 7BE, UK

Contact us / Privacy Policy / Cookie Policy / © Copyright / Created by HTP Digital

Biosciences Building, Crown Street
Liverpool, L69 7BE, UK

Contact us / Privacy Policy / Cookie Policy / © Copyright / Created by HTP Digital